Loading...
Please wait, while we are loading the content...
Similar Documents
Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
| Content Provider | Semantic Scholar |
|---|---|
| Author | Jeong, In-Kyung |
| Copyright Year | 2018 |
| Abstract | In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes. Since 2008, three CVOTs that have studied dipeptidyl peptidase-4 (DPP-4) inhibitors and four CVOTs of a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) have been reported. Each of the completed CVOTs showed the noninferiority of respective drugs to placebo for primary CV composite endpoint. Among them, liraglutide and semaglutide showed a reduction of major adverse cardiovascular events. However, the mechanisms for the observed cardiovascular differences between DPP-4 inhibitors and GLP-1RA, and across individual GLP-1RA are not clearly understood. Therefore, this review will summarize the CVOTs of the DPP-4 inhibitors and GLP-1RA, interpretation of cardioprotective results of incretin-based therapy and the possible mechanism of action. |
| Starting Page | 32 |
| Ending Page | 41 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| DOI | 10.12997/jla.2018.7.1.32 |
| Alternate Webpage(s) | https://synapse.koreamed.org/Synapse/Data/PDFData/0211JLA/jla-7-32.pdf |
| Alternate Webpage(s) | https://doi.org/10.12997/jla.2018.7.1.32 |
| Volume Number | 7 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |